Illumina (NASDAQ:ILMN) Reaches New 12-Month High – Here’s What Happened

Posted by Francis Steltz on Sep 23rd, 2026

Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $254.85 and last traded at $252.2590, with a volume of 189250 shares. The stock had previously closed at $247.46.

Analysts Set New Price Targets

Several research firms have issued reports on ILMN. Royal Bank Of Canada upped their price target on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $135.00 to $260.00 in a research report on Wednesday, September 9th. TD Cowen upped their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. Finally, Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $199.12.

View Our Latest Stock Report on Illumina

Illumina Price Performance

The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a 50-day simple moving average of $206.72 and a 200 day simple moving average of $167.63. The stock has a market capitalization of $37.77 billion, a price-to-earnings ratio of 46.57, a price-to-earnings-growth ratio of 3.38 and a beta of 1.46.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the firm earned $1.19 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Keith Meister sold 457,858 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 2,062,465 shares of company stock valued at $436,589,802 in the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently bought and sold shares of the stock. Fiduciary Financial Advisors acquired a new position in shares of Illumina during the 2nd quarter valued at about $26,000. MCF Advisors LLC boosted its position in Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares during the period. Keating Financial Advisory Services Inc. bought a new stake in Illumina during the second quarter worth approximately $32,000. Rakuten Securities Inc. acquired a new position in Illumina during the second quarter valued at approximately $33,000. Finally, Elevation Wealth Partners LLC raised its position in shares of Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

(Get Free Report)

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.